About HER2-negative breast cancer
HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is expressed less in the tumor. According to the American Society of Clinical Oncology, most of the patients with breast cancer are known to have HER2-negative breast cancer. HER2-negative breast cancer patients can also be hormone receptor positive (HR+). The HER2 protein is found on the outer surface of the breast cells, and the hormone receptors are found inside breast cells. The cancers that have detectable hormone receptors are known as HR+ breast cancer, and those with HER2-negative have a low level of HER2 gene or the HER2 protein. HER2-negative breast cancer can also be HR+ and then the most preferred therapy is hormone therapy. These patients can be treated with chemotherapy or targeted therapy to improve their condition. It can also be treated with platinum-based drugs, and drugs such as capecitabine, eribulin, gemcitabine, ixabepilone, and vinorelbine. These drugs have several adverse effects on patients as some of them can attack the healthy cells of the body while destroying the malignant cells.
Technavio's analysts forecast the global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer. Based on type of drug molecule, the market is segmented as follows:
Technavio Announces the Publication of its Research Report – Global HER2-Negative Breast Cancer Market 2015-2019
Technavio recognizes the following companies as the key players in the Global HER2-Negative Breast Cancer Market: F. Hoffmann-La Roche, Novartis and Pfizer
Other Prominent Vendors in the market are: AbbVie, AstraZeneca, BioMarin, Bristol-Myers Squibb, Eisai, Eli Lilly, Galena Biopharma, Incyte, Merck, Merck Serono, Merrimack, Nektar, and Tesaro.
Commenting on the report, an analyst from Technavio’s team said: “An increase in the patient assistance programs by government organizations and vendors will also boost the market growth. These programs are customized to meet the needs of patients who are unable to afford the expensive therapies.
According to the report, the market is expected to grow because of the significant unmet medical needs across the globe. There has been a growth in the demand for various drugs to treat and prevent HER2-negative breast cancer progression. The present therapies also exhibit several safety issues, which decreases patient compliance. This presents an opportunity for drug makers to develop a therapy that can treat the cancer with better efficacy and safety parameters.
Further, the report states that the market growth may be hampered because of the use of premium-priced therapies. The drugs used to treat HER2-negative breast cancer, including biologic therapies, are expensive. This could lead to treatment withdrawal by patients.
F. Hoffmann-La Roche, Novartis, Pfizer, AbbVie, AstraZeneca, BioMarin, Bristol-Myers Squibb, Eisai, Eli Lilly, Galena Biopharma, Incyte, Merck, Merck Serono, Merrimack, Nektar, Tesaro.